

Manfred Westphal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8848537/publications.pdf>

Version: 2024-02-01

135
papers

7,557
citations

136950

32
h-index

56724

83
g-index

136
all docs

136
docs citations

136
times ranked

11264
citing authors

#	ARTICLE	IF	CITATIONS
1	Traumatic brain injury with concomitant injury to the spleen: characteristics and mortality of a high-risk trauma cohort from the TraumaRegister DGUA®. <i>European Journal of Trauma and Emergency Surgery</i> , 2022, 48, 4451-4459.	1.7	3
2	The Impact of Surgery-Related Muscle Injury on Prevalence and Characteristics of Acute Postcraniotomy Headache – A Prospective Consecutive Case Series. <i>Journal of Neurological Surgery, Part A: Central European Neurosurgery</i> , 2022, 83, 242-251.	0.8	1
3	Combined Subthalamic and Nigral Stimulation Modulates Temporal Gait Coordination and Cortical Gait-Network Activity in Parkinson’s Disease. <i>Frontiers in Human Neuroscience</i> , 2022, 16, 812954.	2.0	6
4	Aneurysm Location Affects Clinical Course and Mortality in Patients With Subarachnoid Hemorrhage. <i>Frontiers in Neurology</i> , 2022, 13, 846066.	2.4	3
5	Single-Center Experience Using a 3D4K Digital Operating Scope System for Aneurysm Surgery. <i>Operative Neurosurgery</i> , 2022, Publish Ahead of Print, .	0.8	2
6	Association of COVID-19 with Intracranial Hemorrhage during Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome: A 10-Year Retrospective Observational Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 28.	2.4	8
7	DNA methylation subclass receptor tyrosine kinase II (RTK II) is predictive for seizure development in glioblastoma patients. <i>Neuro-Oncology</i> , 2022, 24, 1886-1897.	1.2	7
8	Diagnostic potential of extracellular vesicles in meningioma patients. <i>Neuro-Oncology</i> , 2022, 24, 2078-2090.	1.2	6
9	DIPG-42. Diffuse midline gliomas, H3K27-altered as an interdisciplinary challenge. <i>Neuro-Oncology</i> , 2022, 24, i28-i28.	1.2	0
10	TBIO-07. Pediatric tumor classification through genome-wide methylation profiling of extracellular vesicle DNA. <i>Neuro-Oncology</i> , 2022, 24, i184-i184.	1.2	0
11	Cranial bone flap resorption’s pathological features and their implications for clinical treatment. <i>Neurosurgical Review</i> , 2021, 44, 2253-2260.	2.4	10
12	Carbon fiber-reinforced PEEK versus titanium implants: an in vitro comparison of susceptibility artifacts in CT and MR imaging. <i>Neurosurgical Review</i> , 2021, 44, 2163-2170.	2.4	32
13	The faster the better? Time to first CT scan after admission in moderate-to-severe traumatic brain injury and its association with mortality. <i>Neurosurgical Review</i> , 2021, 44, 2697-2706.	2.4	1
14	Intrathecal and systemic alterations of L-arginine metabolism in patients after intracerebral hemorrhage. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 0271678X2098321.	4.3	7
15	CD74 and CD44 Expression on CTCs in Cancer Patients with Brain Metastasis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6993.	4.1	26
16	Genome-wide methylation profiling of glioblastoma cell-derived extracellular vesicle DNA allows tumor classification. <i>Neuro-Oncology</i> , 2021, 23, 1087-1099.	1.2	59
17	IMMU-17. SYSTEMIC IMMUNOSUPPRESSION OF CD4+ T HELPER CELLS IN GLIOMA. <i>Neuro-Oncology</i> , 2021, 23, vi95-vi95.	1.2	0
18	PATH-31. METHYLATION SUBCLASS RECEPTOR TYROSINE KINASE II AS A DRIVER FOR SEIZURES IN IDH-WILDTYPE GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi121-vi122.	1.2	0

#	ARTICLE	IF	CITATIONS
19	BIOM-19. DECIPHERING THE METHYLATION SIGNATURE OF CIRCULATING EXTRACELLULAR VESICLE DNA FOR CNS TUMOR CLASSIFICATION. <i>Neuro-Oncology</i> , 2021, 23, vi14-vi14.	1.2	0
20	BIOM-39. METHYLATION AND MUTATION PROFILES IN MENINGIOMA CELL-DERIVED EXTRACELLULAR VESICLE DNA REFLECT EPIGENETIC AND GENOMIC ALTERATIONS IN ORIGINAL TUMORS. <i>Neuro-Oncology</i> , 2021, 23, vi19-vi19.	1.2	0
21	PATH-39. INTEGRATED MOLECULAR-MORPHOLOGICAL MENINGIOMA CLASSIFICATION: A MULTICENTER RETROSPECTIVE ANALYSIS, RETRO- AND PROSPECTIVELY VALIDATED. <i>Neuro-Oncology</i> , 2021, 23, vi123-vi124.	1.2	0
22	Enhancing Safety in Epilepsy Surgery (EASINESS): Study Protocol for a Retrospective, Multicenter, Open Registry. <i>Frontiers in Neurology</i> , 2021, 12, 782666.	2.4	1
23	Operative versus non-operative treatment of traumatic brain injuries in patients 80 years of age or older. <i>Neurosurgical Review</i> , 2020, 43, 1305-1314.	2.4	6
24	FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas. <i>Acta Neuropathologica</i> , 2020, 139, 175-192.	7.7	15
25	Decompressive craniectomy in malignant MCA infarction in times of mechanical thrombectomy. <i>Acta Neurochirurgica</i> , 2020, 162, 3147-3152.	1.7	17
26	A Comparison between Pediatric and Adult Patients after Cranioplasty: Aseptic Bone Resorption Causes Earlier Revision in Children. <i>Journal of Neurological Surgery, Part A: Central European Neurosurgery</i> , 2020, 81, 227-232.	0.8	8
27	Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 659-670.	2.5	14
28	Immune Characterization in Aneurysmal Subarachnoid Hemorrhage Reveals Distinct Monocytic Activation and Chemokine Patterns. <i>Translational Stroke Research</i> , 2020, 11, 1348-1361.	4.2	32
29	Features of tumor texture influence surgery and outcome in intracranial meningioma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa113.	0.7	4
30	Parkinson's disease uncovers an underlying sensitivity of subthalamic nucleus neurons to beta-frequency cortical input in vivo. <i>Neurobiology of Disease</i> , 2020, 146, 105119.	4.4	14
31	Sex Disparities in the Self-Evaluation of Subthalamic Deep Brain Stimulation Effects on Mood and Personality in Parkinson's Disease Patients. <i>Frontiers in Neurology</i> , 2020, 11, 776.	2.4	8
32	Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay. <i>Cells</i> , 2020, 9, 2337.	4.1	13
33	Exome sequencing in 38 patients with intracranial aneurysms and subarachnoid hemorrhage. <i>Journal of Neurology</i> , 2020, 267, 2533-2545.	3.6	14
34	Initial pupil status is a strong predictor for in-hospital mortality after aneurysmal subarachnoid hemorrhage. <i>Scientific Reports</i> , 2020, 10, 4764.	3.3	19
35	FASN Is a Biomarker Enriched in Malignant Glioma-Derived Extracellular Vesicles. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1931.	4.1	20
36	Genome-wide DNA methylation profiles distinguish silent from non-silent ACTH adenomas. <i>Acta Neuropathologica</i> , 2020, 140, 95-97.	7.7	7

#	ARTICLE	IF	CITATIONS
37	Molecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape. <i>Acta Neuropathologica Communications</i> , 2020, 8, 28.	5.2	24
38	Damage to the eye and optic nerve in seriously traumatized patients with concomitant head injury: analysis of 84,627 cases from the TraumaRegister DGUA® between 2002 and 2015. <i>Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine</i> , 2020, 28, 15.	2.6	2
39	CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. <i>Acta Neuropathologica</i> , 2020, 140, 409-413.	7.7	116
40	The burden of headache following aneurysmal subarachnoid hemorrhage: a prospective single-center cross-sectional analysis. <i>Acta Neurochirurgica</i> , 2020, 162, 893-903.	1.7	31
41	Pallidal lead placement in dystonia: leads of non-responders are contained within an anatomical range defined by responders. <i>Journal of Neurology</i> , 2020, 267, 1663-1671.	3.6	16
42	Local Intracerebral Immunomodulation Using Interleukin-Expressing Mesenchymal Stem Cells in Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 2626-2639.	7.0	31
43	Quantitative Sensory Changes Following Gasserian Ganglion Radiofrequency Thermocoagulation in Patients with Medical Refractory Trigeminal Neuralgia: A Prospective Consecutive Case Series. <i>Journal of Neurological Surgery, Part A: Central European Neurosurgery</i> , 2020, 81, 423-429.	0.8	0
44	Seizures as presenting symptom in patients with glioblastoma. <i>Epilepsia</i> , 2019, 60, 149-154.	5.1	22
45	Temporal evolution of beta bursts in the parkinsonian cortical and basal ganglia network. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 16095-16104.	7.1	98
46	Immunologic Profiling of Mutational and Transcriptional Subgroups in Pediatric and Adult High-Grade Gliomas. <i>Cancer Immunology Research</i> , 2019, 7, 1401-1411.	3.4	35
47	Early clinical course after aneurysmal subarachnoid hemorrhage: comparison of patients treated with Woven EndoBridge, microsurgical clipping, or endovascular coiling. <i>Acta Neurochirurgica</i> , 2019, 161, 1763-1773.	1.7	4
48	Clonality of circulating tumor cells in breast cancer brain metastasis patients. <i>Breast Cancer Research</i> , 2019, 21, 101.	5.0	54
49	Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas. <i>Clinical Cancer Research</i> , 2019, 25, 5260-5270.	7.0	23
50	Local Therapies. , 2019, , 159-172.		0
51	Tumors of the Pineal Region. , 2019, , 283-299.		0
52	Postoperative Nausea and Vomiting Following Craniotomy: Risk Factors and Complications in Context of Perioperative High-dose Dexamethasone Application. <i>Journal of Neurological Surgery, Part A: Central European Neurosurgery</i> , 2019, 80, 381-386.	0.8	5
53	EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients. <i>Scientific Reports</i> , 2019, 9, 7406.	3.3	73
54	Identification of KIF11 As a Novel Target in Meningioma. <i>Cancers</i> , 2019, 11, 545.	3.7	31

#	ARTICLE	IF	CITATIONS
55	Imaging flow cytometry facilitates multiparametric characterization of extracellular vesicles in malignant brain tumours. <i>Journal of Extracellular Vesicles</i> , 2019, 8, 1588555.	12.2	86
56	Relapse of a group 4 medulloblastoma after 18 years as proven by histology and DNA methylation profiling. <i>Child's Nervous System</i> , 2019, 35, 1029-1033.	1.1	1
57	Synchronised spiking activity underlies phase amplitude coupling in the subthalamic nucleus of Parkinson's disease patients. <i>Neurobiology of Disease</i> , 2019, 127, 101-113.	4.4	49
58	CSIG-09. PROTEOMIC ANALYSIS OF MENINGIOMA CELL-DERIVED EXTRACELLULAR VESICLES: FIRST OF A KIND. <i>Neuro-Oncology</i> , 2019, 21, vi45-vi46.	1.2	0
59	CSIG-11. CENTRAL NERVOUS SYSTEM TUMOR PATIENTS HAVE ELEVATED LEVELS OF CIRCULATING EXTRACELLULAR VESICLES. <i>Neuro-Oncology</i> , 2019, 21, vi46-vi46.	1.2	0
60	RARE-26. WHOLE GENOME SEQUENCING OF AN OSSEOUS METASTASIS DURING CHECKPOINT-CONTROLLED INTRACRANIAL GLIOBLASTOMA REVEALS NEW INSIGHTS INTO POTENTIAL MECHANISMS OF IMMUNE ESCAPE. <i>Neuro-Oncology</i> , 2019, 21, vi227-vi227.	1.2	0
61	CBMT-12. FOCAD LOSS IMPACTS MICROTUBULE ASSEMBLY, G2/M PROGRESSION AND PATIENT SURVIVAL IN ASTROCYTIC GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi35-vi35.	1.2	0
62	MNGI-02. FEATURES OF TUMOR TEXTURE INFLUENCE SURGERY AND OUTCOME IN INTRACRANIAL MENINGIOMA. <i>Neuro-Oncology</i> , 2019, 21, vi139-vi139.	1.2	0
63	GENE-23. GENOME-WIDE DNA METHYLATION PROFILES DISTINGUISH SILENT FROM NON-SILENT ACTH ADENOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi102-vi102.	1.2	0
64	PATH-53. IMMUNOLOGICAL PROFILING OF MUTATIONAL AND TRANSCRIPTIONAL SUBGROUPS IN PEDIATRIC AND ADULT HIGH-GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi155-vi155.	1.2	0
65	IMMU-40. CANCER IMMUNOEDITING SHAPES THE IMMUNE ESCAPE SIGNATURE AND CLONAL ARCHITECTURE IN GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi127-vi127.	1.2	0
66	GENE-22. GENOME-WIDE METHYLATION PROFILING OF GLIOBLASTOMA EXTRACELLULAR VESICLE DNA ALLOWS TUMOR CLASSIFICATION. <i>Neuro-Oncology</i> , 2019, 21, vi102-vi102.	1.2	0
67	A comparison between threshold criterion and amplitude criterion in transcranial motor evoked potentials during surgery for supratentorial lesions. <i>Journal of Neurosurgery</i> , 2019, 131, 740-749.	1.6	9
68	Phase-Dependent Suppression of Beta Oscillations in Parkinson's Disease Patients. <i>Journal of Neuroscience</i> , 2019, 39, 1119-1134.	3.6	89
69	Electrical Stimulation of the Anterior Thalamus for Epilepsy: Clinical Outcome and Analysis of Efficient Target. <i>Neuromodulation</i> , 2019, 22, 465-471.	0.8	33
70	Preclinical analysis of human mesenchymal stem cells: tumor tropism and therapeutic efficiency of local HSV-TK suicide gene therapy in glioblastoma. <i>Oncotarget</i> , 2019, 10, 6049-6061.	1.8	28
71	Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. <i>Science Advances</i> , 2018, 4, eaar2766.	10.3	416
72	Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes. <i>Clinical Cancer Research</i> , 2018, 24, 4187-4200.	7.0	114

#	ARTICLE	IF	CITATIONS
73	Influence of antithrombotic agents on recurrence rate and clinical outcome in patients operated for chronic subdural hematoma. <i>Neurocirugia</i> , 2018, 29, 86-92.	0.4	14
74	Spatio-temporal dynamics of cortical drive to human subthalamic nucleus neurons in Parkinson's disease. <i>Neurobiology of Disease</i> , 2018, 112, 49-62.	4.4	58
75	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018, 555, 469-474.	27.8	1,872
76	RARE-19. CHEMOTHERAPY FOR SPINAL GLIOMAS IN ADULTS: A RETROSPECTIVE STUDY. <i>Neuro-Oncology</i> , 2018, 20, vi240-vi240.	1.2	1
77	CBMT-12. FATTY ACID SYNTHASE POSITIVE EVs AS NOVEL BIOMARKERS IN BRAIN CANCER.. <i>Neuro-Oncology</i> , 2018, 20, vi34-vi35.	1.2	0
78	IMMU-55. IMMUNOMODULATORY IL-7 AND IL-12-EXPRESSING MSCs INDUCE LONG-TERM SURVIVAL AND IMMUNITY IN SYNGENEIC INTRACEREBRAL GLIOBLASTOMA MODELS. <i>Neuro-Oncology</i> , 2018, 20, vi133-vi134.	1.2	0
79	CSIG-27. DIFFERENTIAL ELEVATION OF TERT ACTIVITY AND SENSITIVITY TO TEMOZOLOMIDE BY TYPE OF TERT MUTATION IN MGMT PROMOTER-METHYLATED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi48-vi49.	1.2	0
80	IMMU-44. OPTICAL BARCODING TO INVESTIGATE CLONAL DYNAMICS OF GBM HIGHLIGHTS THE INTRINSIC CAPACITY OF GBM TO RE-ACTIVATE DEVELOPMENTAL GENES AND ESCAPE IMMUNE SURVEILLANCE. <i>Neuro-Oncology</i> , 2018, 20, vi131-vi131.	1.2	0
81	IMMU-49. CYTOTOXIC T CELLS AND THEIR ACTIVATION STATUS ARE INDEPENDENT PROGNOSTIC MARKERS IN MENINGIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi132-vi132.	1.2	0
82	Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease. <i>Cancers</i> , 2018, 10, 527.	3.7	45
83	Intrathecal penetration of meropenem and vancomycin administered by continuous infusion in patients suffering from ventriculitis—a retrospective analysis. <i>Acta Neurochirurgica</i> , 2018, 160, 2099-2105.	1.7	17
84	Best practices for the use of intracerebroventricular drug delivery devices. <i>Molecular Genetics and Metabolism</i> , 2018, 124, 184-188.	1.1	44
85	Extensive Spinal Adhesive Arachnoiditis After Extradural Spinal Infection—“Spinal Dura Mater Is No Barrier to Inflammation. <i>World Neurosurgery</i> , 2018, 116, e1194-e1203.	1.3	10
86	DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment. <i>Neuro-Oncology</i> , 2018, 20, 1616-1624.	1.2	65
87	The secreted glycolytic enzyme GPI/AMF stimulates glioblastoma cell migration and invasion in an autocrine fashion but can have anti-proliferative effects. <i>Neuro-Oncology</i> , 2018, 20, 1594-1605.	1.2	21
88	First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. <i>Journal of Translational Medicine</i> , 2018, 16, 142.	4.4	376
89	Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma. <i>Acta Neuropathologica Communications</i> , 2018, 6, 81.	5.2	22
90	Introduction. Update on adult neuro-oncology. <i>Neurosurgical Focus</i> , 2018, 44, E1.	2.3	0

#	ARTICLE	IF	CITATIONS
91	Tectal gliomas: assessment of malignant progression, clinical management, and quality of life in a supposedly benign neoplasm. <i>Neurosurgical Focus</i> , 2018, 44, E15.	2.3	12
92	Optical Barcoding for Single-Clone Tracking to Study Tumor Heterogeneity. <i>Molecular Therapy</i> , 2017, 25, 621-633.	8.2	32
93	Irreversible Total Loss of Brain Function and Organ Donation in Patients with Aneurysmal Subarachnoid Hemorrhage. <i>World Neurosurgery</i> , 2017, 105, 492-497.	1.3	3
94	Morphology of Ruptured and Unruptured Intracranial Aneurysms. <i>World Neurosurgery</i> , 2017, 99, 610-617.	1.3	51
95	Rare ADAR and RNASEH2B variants and a type I interferon signature in glioma and prostate carcinoma risk and tumorigenesis. <i>Acta Neuropathologica</i> , 2017, 134, 905-922.	7.7	12
96	Body Mass Index >35 as Independent Predictor of Mortality in Severe Traumatic Brain Injury. <i>World Neurosurgery</i> , 2017, 107, 515-521.	1.3	16
97	EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise. <i>CNS Drugs</i> , 2017, 31, 723-735.	5.9	162
98	PTEN mediates the cross talk between breast and glial cells in brain metastases leading to rapid disease progression. <i>Oncotarget</i> , 2017, 8, 6155-6168.	1.8	35
99	Chemotherapy for intracranial ependymoma in adults. <i>BMC Cancer</i> , 2016, 16, 287.	2.6	23
100	From Abstract to Publication in a Peer-Reviewed Journal: Evaluation of the 63rd Annual Meeting of the German Society of Neurosurgery. <i>Journal of Neurological Surgery, Part A: Central European Neurosurgery</i> , 2016, 77, 046-051.	0.8	7
101	Complications of glioma surgery. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2016, 134, 201-218.	1.8	38
102	Terson's syndrome – Pathophysiologic considerations of an underestimated concomitant disease in aneurysmal subarachnoid hemorrhage. <i>Journal of Clinical Neuroscience</i> , 2016, 33, 182-186.	1.5	19
103	Neuropsychological performance and seizure control after subsequent anteromesial temporal lobe resection following selective amygdalohippocampectomy. <i>Epilepsia</i> , 2016, 57, 1789-1797.	5.1	7
104	Long-term vestibulocochlear functional outcome following retro-sigmoid approach to resection of vestibular schwannoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 719-725.	1.6	15
105	A novel threshold criterion in transcranial motor evoked potentials during surgery for gliomas close to the motor pathway. <i>Journal of Neurosurgery</i> , 2016, 125, 795-802.	1.6	30
106	New Radiologic Parameters Predict Clinical Outcome after Decompressive Craniectomy. <i>World Neurosurgery</i> , 2016, 88, 519-525.e1.	1.3	10
107	Epidermal growth factor receptor overexpression is common and not correlated to gene copy number in ependymoma. <i>Child's Nervous System</i> , 2016, 32, 281-290.	1.1	7
108	Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition. <i>Targeted Oncology</i> , 2016, 11, 29-40.	3.6	34

#	ARTICLE	IF	CITATIONS
109	EGFR gene amplification and variant III (EGFRvIII) mutation in primary and recurrent glioblastoma.. Journal of Clinical Oncology, 2016, 34, 2042-2042.	1.6	3
110	Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade. Oncotarget, 2016, 7, 14551-14568.	1.8	36
111	METB-06THE GLYCOLYSIS ENZYME GLUCOSE 6-PHOSPHATE ISOMERASE (GPI) STIMULATES GLIOBLASTOMA CELL MOTILITY IN AN AUTOCRINE FASHION. Neuro-Oncology, 2015, 17, v136.2-v136.	1.2	0
112	A 19-year-old Male with an Intraventricular Tumor. Brain Pathology, 2015, 25, 657-658.	4.1	1
113	Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients. Oncotarget, 2015, 6, 13579-13590.	1.8	21
114	A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. European Journal of Cancer, 2015, 51, 522-532.	2.8	161
115	METB-05GLYCOLYSIS AND THE PENTOSE PHOSPHATE PATHWAY ARE DIFFERENTIALLY ASSOCIATED WITH THE DICHOTOMOUS REGULATION OF GLIOBLASTOMA CELL MIGRATION VERSUS PROLIFERATION. Neuro-Oncology, 2015, 17, v136.1-v136.	1.2	1
116	Inhibition of intracerebral glioblastoma growth by targeting the insulin-like growth factor 1 receptor involves different context-dependent mechanisms. Neuro-Oncology, 2015, 17, 1076-1085.	1.2	27
117	Synchronized cortico-subthalamic beta oscillations in Parkin-associated Parkinson's disease. Clinical Neurophysiology, 2015, 126, 2241-2243.	1.5	9
118	The simplified acute physiology score II to predict hospital mortality in aneurysmal subarachnoid hemorrhage. Acta Neurochirurgica, 2015, 157, 2051-2059.	1.7	10
119	Validation of the modified Graeb score in aneurysmal subarachnoid hemorrhage. Acta Neurochirurgica, 2015, 157, 1867-1872.	1.7	14
120	Pineal Lesions: A Multidisciplinary Challenge. Advances and Technical Standards in Neurosurgery, 2015, 42, 79-102.	0.5	13
121	Molecular classification of diffuse cerebral gliomas using genome- and transcriptome-wide profiling.. Journal of Clinical Oncology, 2015, 33, 2007-2007.	1.6	1
122	REPEATED INTRANASAL APPLICATION OF NEURAL STEM CELL-MEDIATED ENZYM/PRODRUG THERAPY USING A NOVEL HSV-THYMIDINE KINASE VARIANT IMPROVES THERAPEUTIC EFFICIENCY IN AN INTRACRANIAL GLIOBLASTOMA MODEL. Neuro-Oncology, 2014, 16, iii50-iii50.	1.2	6
123	"GO OR GROW" - LINKS BETWEEN CELLULAR FUNCTION, GLUCOSE METABOLISM AND GLIOMA MICROENVIRONMENT. Neuro-Oncology, 2014, 16, iii6-iii6.	1.2	1
124	Hematogenous dissemination of glioblastoma multiforme. Science Translational Medicine, 2014, 6, 247ra101.	12.4	264
125	Vascular events after transylvian selective amygdalohippocampectomy and impact on epilepsy outcome. Epilepsia, 2014, 55, 763-769.	5.1	24
126	High-Frequency Stimulation of the Subthalamic Nucleus Counteracts Cortical Expression of Major Histocompatibility Complex Genes in a Rat Model of Parkinson's Disease. PLoS ONE, 2014, 9, e91663.	2.5	7

#	ARTICLE	IF	CITATIONS
127	Ocular Ultrasound as an Easy Applicable Tool for Detection of Terson's Syndrome after Aneurysmal Subarachnoid Hemorrhage. PLoS ONE, 2014, 9, e114907.	2.5	12
128	Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2013, 14, 823-833.	10.7	192
129	Nimotuzumab treatment of malignant gliomas. Expert Opinion on Biological Therapy, 2012, 12, 1649-1659.	3.1	53
130	Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. Acta Neurochirurgica, 2011, 153, 1211-1218.	1.7	168
131	Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro-Oncology, 2010, 12, 871-881.	1.2	407
132	Vascular endothelial growth factor-stimulated cerebral microvascular endothelial cells mediate the recruitment of neural stem cells to the neurovascular niche. Brain Research, 2009, 1268, 24-37.	2.2	75
133	Inhibition of Glioblastoma Growth in a Highly Invasive Nude Mouse Model Can Be Achieved by Targeting Epidermal Growth Factor Receptor but not Vascular Endothelial Growth Factor Receptor-2. Clinical Cancer Research, 2008, 14, 5447-5458.	7.0	84
134	A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncology, 2003, 5, 79-88.	1.2	1,071
135	Treatment of Nongerminomatous Germ-Cell Tumors of the Pineal Region. Neurosurgery, 1994, 34, 524-529.	1.1	85